Literature DB >> 19204936

Nitric oxide-mediated inhibition of NFkappaB regulates hyperthermia-induced apoptosis.

Natarajan Aravindan1, Sumathy Mohan, Terence S Herman, Mohan Natarajan.   

Abstract

Ascertaining the upstream regulatory mechanisms of hyperthermia-induced apoptosis is important to understand the role of hyperthermia in combined modality cancer therapy. Accordingly, we investigated whether (i) hyperthermia-induced apoptosis is mediated through the nitric oxide (NO) signaling pathway and (ii) inhibition of post-translational modification of IkappaBalpha and down regulation of NFkappaB-DNA binding activity is an intermediate step in NO-dependent apoptosis in MCF-7 breast cancer cells. For hyperthermia treatment, the cells were exposed to 43 degrees C. Intracellular NO levels measured by the fluorescent intensity of DAF-2A and iNOS expression by immunobloting revealed an increased level of iNOS dependent NO production after 43 degrees C. Apoptosis measured by Annexin V expression and cell survival by clonogenic assay showed a 20% increase in apoptosis after 43 degrees C treatments. EMSA analysis showed a dose-dependent inhibition of NFkappaB-DNA binding activity. The hyperthermia-mediated inhibition of NFkappaB was persistent even after 48 h. Inhibition of NO by L-NAME rescued the NFkappaB-DNA binding activity and inhibits heat-induced apoptosis. Similarly, over-expression of NFkappaB by transient transfection inhibits heat-induced apoptosis. These results demonstrate that apoptosis upon hyperthermia exposure of MCF-7 cells is regulated by NO-mediated suppression of NFkappaB. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19204936     DOI: 10.1002/jcb.22079

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  7 in total

1.  The resistance of breast cancer stem cells to conventional hyperthermia and their sensitivity to nanoparticle-mediated photothermal therapy.

Authors:  Andrew R Burke; Ravi N Singh; David L Carroll; James C S Wood; Ralph B D'Agostino; Pulickel M Ajayan; Frank M Torti; Suzy V Torti
Journal:  Biomaterials       Date:  2012-01-14       Impact factor: 12.479

2.  Acquired tumor cell radiation resistance at the treatment site is mediated through radiation-orchestrated intercellular communication.

Authors:  Natarajan Aravindan; Sheeja Aravindan; Vijayabaskar Pandian; Faizan H Khan; Satish Kumar Ramraj; Praveen Natt; Mohan Natarajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-07       Impact factor: 7.038

3.  Curcumin regulates low-linear energy transfer γ-radiation-induced NFκB-dependent telomerase activity in human neuroblastoma cells.

Authors:  Natarajan Aravindan; Jamunarani Veeraraghavan; Rakhesh Madhusoodhanan; Terence S Herman; Mohan Natarajan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-13       Impact factor: 7.038

4.  Radiation-triggered tumor necrosis factor (TNF) alpha-NFkappaB cross-signaling favors survival advantage in human neuroblastoma cells.

Authors:  Jamunarani Veeraraghavan; Mohan Natarajan; Sheeja Aravindan; Terence S Herman; Natarajan Aravindan
Journal:  J Biol Chem       Date:  2011-04-28       Impact factor: 5.157

5.  Mitochondria and reactive oxygen species: physiology and pathophysiology.

Authors:  Subhashini Bolisetty; Edgar A Jaimes
Journal:  Int J Mol Sci       Date:  2013-03-19       Impact factor: 5.923

6.  Activation of cGMP/PKG/p65 signaling associated with PDE5-Is downregulates CCL5 secretion by CD8 + T cells in benign prostatic hyperplasia.

Authors:  Song Jin; Peng Xiang; Jie Liu; Yang Yang; Shuai Hu; Jindong Sheng; Qun He; Wei Yu; Wenke Han; Jie Jin; Jing Peng
Journal:  Prostate       Date:  2019-04-08       Impact factor: 4.104

7.  Novel synthetic monoketone transmute radiation-triggered NFκB-dependent TNFα cross-signaling feedback maintained NFκB and favors neuroblastoma regression.

Authors:  Sheeja Aravindan; Mohan Natarajan; Vibhudutta Awasthi; Terence S Herman; Natarajan Aravindan
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.